Moderate to Severe Atopic Dermatitis: Targeted Pathways and Strategies to Personalize Patient Care

Expert pharmacist clinicians discuss the latest on emerging therapies for atopic dermatitis, strategies to engage patients in shared decision-making, and updates on vaccination best practices in immunocompromised patients. 

Agenda

12:00 PM Welcome and Opening Remarks

12:05 PM AD Overview, Disease Burden, and Impact on Quality of Life

12:20 PM Current and Emerging Therapies in AD

12:40 PM Patient Case Discussions

12:50 PM Enhancing Patient Engagement

1:05 PM Role of Vaccinations in Patients Receiving Immunotherapies

1:15 PM Question and Answer Session

1:30 PM Adjournment

Events

Date / Time
Event Details

Faculty

Faculty
Sarah Lant, PharmD

Clinical Pharmacist Specialist
UChicago Medicine
Chicago, Illinois

Faculty
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES

Associate Professor of Pharmacy Practice
Duquesne University Mylan School of Pharmacy
Pittsburgh, Pennsylvania

Program Overview
Expert pharmacist clinicians discuss the latest on emerging therapies for atopic dermatitis, strategies to engage patients in shared-decision making, and updates on vaccination best practices in immunocompromised patients in a CE-certified program featuring a live 90-minute webinar with downloadable slides.

Goal Statement
The goal of this activity is to improve the knowledge and competence of pharmacists about current and emerging treatment options for moderate to severe AD, engaging patients in AD care, and recommendations for vaccinations in patients who are receiving immunosuppressants and immunomodulatory therapies.

Target Audience
The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists who care for patients with atopic dermatitis, and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the underlying pathophysiology of moderate to severe AD, including inflammatory pathways and associated drug targets
  • Summarize the safety and efficacy of current and emerging targeted treatments for moderate to severe AD in children, adolescents, and adults
  • Incorporate shared decision-making and patient engagement into treatment selection for moderate to severe AD
  • Identify recommendations and best practices for herpes zoster and COVID-19 vaccination in patients with AD who are receiving immunosuppressants and immunomodulatory therapies

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-160-L01-P has been assigned to this live knowledge-based activity (initial release date 5/19/2022). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.